Genomics Editing & Analysis Lab · Hanyang University

Three connected lines of work: reading DNA, RNA, and epigenetic information — including screening-based studies of mechanism — building the software that makes those measurements usable, and turning both into therapies. We develop methods to analyze the information embedded in DNA and RNA. Our research connects data across genetics and epigenetics — sequences, large mutations, and base modifications — and uses pooled screening to trace how those changes drive cellular and disease mechanisms. We build software for analyzing DNA and RNA information — tools for newly developed methods, and tools that work around the limits of existing ones. They are designed as web platforms so that anyone can use them without installing anything. Earlier web toolkits developed by the PI include BE-Designer / BE-Analyzer, PE-Designer / PE-Analyzer, CRISPR-Sub, and the Digenome-seq web tool. We develop CRISPR-based gene therapies with a focus on validating their performance and safety. Our targets include genetic disorders and non-genetic disease alike, and the same approaches let us study disease mechanisms directly in human cells. We read the information written in DNA and RNA — and rewrite it. Our work spans CRISPR-based gene therapy, genetics and epigenetics, screening-based studies of disease mechanism, and open web tools for the community. Sequences, large structural variants, and base modifications — and screening-based approaches that connect them to disease mechanism. Web-based tools that make new methods usable by anyone — from BE-Designer and PE-Analyzer to CRISPRLungo. Base and prime editing therapeutics, validated for efficiency and safety — for genetic and non-genetic disease alike.